Abstract
Introduction: This study explored cannabis use for pain relief among socially marginalised Nigerian women in the context of barriers to pain management.
Methods: The study was designed as a qualitative exploratory study of pain experience and management. Sixteen in-depth, individual interviews were conducted with street-involved women who use drugs and had chronic pain. Transcripts were coded and analysed thematically.
Results: Pain was experienced as a pervasive feature of everyday life that disrupted daily routines, affected economic activities, strained social relationships and had adverse effects on health and wellbeing. Participants sought treatment in health facilities, but faced social and health system barriers to service utilisation including financial cost of services, dismissal of symptoms by providers, stigma due to physical appearance, substance use and lack of social support. These barriers encouraged disengagement from services and reliance on cannabis (along with heroin and diverted prescription opioids) for pain management. Cannabis use relieved pain and improved daily functioning, enabling participants to undertake economic activities. However, using cannabis to enhance the effects of opioids and heavy and long-term use owing to pain chronicity and disability generated concerns about harms.
Discussion and conclusions: Findings show the therapeutic benefits of cannabis in the face of barriers to pain management. This support calls to explore the potentials of cannabis for pain management for socially marginalised populations and to develop medical guidelines to reduce the risk of adverse health consequences. Therapeutic cannabis, provided based on medical guidance, could improve pain management for socially marginalised populations.
Keywords: cannabis, chronic pain, health service barriers, pain management, stigma
© 2022 Australasian Professional Society on Alcohol and other Drugs.
Similar articles
-
Abstracts of Presentations at the Association of Clinical Scientists 143rd Meeting Louisville, KY May 11-14,2022.Ann Clin Lab Sci. 2022 May;52(3):511-525.PMID: 35777803
-
Prescription of Controlled Substances: Benefits and Risks.2022 Jul 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.PMID: 30726003 Free Books & Documents.
-
Florida Controlled Substance Prescribing.2022 Jun 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.PMID: 33428370 Free Books & Documents.
-
Cannabis-based medicines for chronic neuropathic pain in adults.Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2.PMID: 29513392 Free PMC article. Review.
-
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.Cochrane Database Syst Rev. 2022 May 5;5(5):CD013444. doi: 10.1002/14651858.CD013444.pub2.PMID: 35510826 Review.
References
REFERENCES
-
- Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018;3:e341-50.
-
- Lucas P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. J Psychoactive Drugs. 2012;44:125-33.
-
- Hutchison KE, Hagerty SL, Galinkin J, Bryan AD, Bidwell LC. Cannabinoids, pain, and opioid use reduction: the importance of distilling and disseminating existing data. Cannabis Cannabinoid Res. 2019;4:158-64.
-
- Dassieu L, Kaboré J-L, Choinière M, Arruda N, Roy É. Painful lives: chronic pain experience among people who use illicit drugs in Montreal (Canada). Soc Sci Med. 2020;246:112734.
-
- Zimmer Z, Rubin S. Pain and disablement. In: Jagger C, Crimmins EM, Saito Y, Yokota R, Oyen HV, Robine J, editors. International handbook of health expectancies. Switzerland AG: Springer; 2020. p. 219-32.